Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer.
Daisuke MorinagaHajime AsahinaShotaro ItoOsamu HonjoHisashi TanakaRyoichi HondaHiroshi YokouchiKeiichi NakamuraKei TakamuraFumihiro HommuraYasutaka KawaiKenichiro ItoNoriaki SukohKeiki YokooRyo MoritaToshiyuki HaradaTaichi TakashinaTomohiro GodaHirotoshi Dosaka-AkitaHiroshi Isobenull nullPublished in: Cancer medicine (2023)
ICI is also effective in elderly NSCLC patients, and treatment discontinuation due to irAEs may be a good prognostic marker.